Clinical Trial Update: Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing IMP321 (eftilagimod alpha) for advanced solid tumors reports feasibility and safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Peritoneal Carcinomatosis
• Urothelial Carcinoma

Drugs mentioned

• IMP321 (eftilagimod alpha) (eftilagimod alpha)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Solid Tumors, Peritoneal Carcinomatosis | Phase 1 | Status: ACTIVE_NOT_RECRUITING